Liquid biopsy-based detection of minimal residual disease(MRD)has been widely used in clinical oncology.The next general sequencing(NGS),as an emerging technique of MRD detection provides quantitative and qualitative analysis of circulating tumor DNA(ctDNA)for solid tumors with high sensitivity and high specificity.Recent studies have demonstrated that the ctDNA-based MRD detection has significant advantages over traditional methods in recurrence prediction,prognosis determination,efficacy assessment and individualized stratified treatment of various malignant tumors.However,for its routine clinical application large amount of clinical evidence are needed and the standardization of detection methods is required.
维普
万方数据